Strategic Partners A/S

Strategic Partners A/S Intangible Assets

Intangible Assets of Strategic Partners A/S (STRAP.CO) as of Oct 16, 2026.

Intangible Assets

0.00DKK

Last updated:

Intangible Assets of Strategic Partners A/S is 2023 0.00 DKK. Intangible Assets of Strategic Partners A/S was 2022 0.00 DKK. It decreases by % lower compared to the previous year.

The Strategic Partners A/S Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2014
0.00 DKK
Jan 1, 2017
9.85 M DKK
Jan 1, 2018
10.74 M DKK
Jan 1, 2019
10.54 M DKK
Jan 1, 2020
12.45 M DKK
Jan 1, 2021
2.15 M DKK
Jan 1, 2022
0.00 DKK
Jan 1, 2023
0.00 DKK
The Strategic Partners A/S Intangible Assets history
YEARIntangible AssetsYoY
0.00DKK—
0.00DKK-100.00%
2.15 MDKK-82.72%
12.45 MDKK+18.17%
10.54 MDKK-1.91%
10.74 MDKK+9.04%
9.85 MDKK—
0.00DKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strategic Partners A/S Stock analysis

What does Strategic Partners A/S do? Strategic Partners A/S, listed on the Copenhagen Stock Exchange with ticker STRAP.CO and ISIN DK0062502894, is a Danish biotechnology company operating in the healthcare sector. Based in Copenhagen, the company employs 141 people and went public through an IPO on November 17, 2017. Strategic Partners A/S focuses on the development of treatments for rare diseases, particularly targeting lysosomal storage diseases (LSDs) and protein aggregation disorders. LSDs encompass approximately 50 genetic disorders caused by deficiencies in lysosomal enzymes or other lysosomal components. The company's primary therapeutic candidate, arimoclomol, works by stimulating the production of heat shock proteins, which assist in correcting misfolded proteins or facilitating their removal via lysosomal recycling. Strategic Partners A/S collaborates with academic institutions across Europe and the United States to advance its research and development efforts. The company's website is hosted at https://www.orphazyme.com/, though the provided source description includes unverified details about Orphazyme A/S, which should not be conflated with Strategic Partners A/S. Strategic Partners A/S is dedicated to addressing life-threatening and debilitating rare diseases through innovative biotechnological approaches. The company's operations are centered on preclinical development, with a focus on advancing therapies that target the underlying mechanisms of genetic disorders. Strategic Partners A/S maintains a strong presence in the biotechnology sector, leveraging partnerships and scientific expertise to develop treatments for conditions with limited therapeutic options. The company's activities are aligned with the broader healthcare industry's focus on rare disease research and treatment innovation. Strategic Partners A/S continues to work toward bringing novel therapies to patients suffering from rare and complex genetic disorders. Strategic Partners A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strategic Partners A/S stock

On Eulerpool you can find the complete historical development of Intangible Assets Strategic Partners A/S since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Strategic Partners A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Strategic Partners A/S

All Key Metrics — Strategic Partners A/S